Allergan licenses AstraZeneca drug | Chemical & Engineering News
Volume 94 Issue 40 | p. 15 | Concentrates
Issue Date: October 10, 2016

Allergan licenses AstraZeneca drug

Department: Business
Keywords: biologics, antibody, licensing, Crohn’s disease, ulcerative colitis, IL-23

Allergan will pay $250 million up front and up to $1.3 billion more in milestone payments over 15 years for rights to the AstraZeneca anti-IL-23 monoclonal antibody MEDI2070. AstraZeneca will pay one-third of the money it receives to Amgen, its partner in developing MEDI2070. The antibody is in Phase IIb clinical trials for treating Crohn’s disease and is ready to enter Phase II trials for ulcerative colitis. AstraZeneca says the target diseases fall outside its focus areas.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment